CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects

Dezentje, V.O.; Opdam, F.L.; Gelderblom, H.; Hartigh, J. den; Straaten, T. van der; Vree, R.; ... ; Guchelaar, H.J. (2015)

Article / Letter to editor

• CYP2D6
• Endoxifen
• Early breast cancer

• All authors: Dezentje, V.O.; Opdam, F.L.; Gelderblom, H.; Hartigh, J. den; Straaten, T. van der; Vree, R.; Maartense, E.; Smorenburg, C.H.; Putter, H.; Dieudonne, A.S.; Neven, P.; Velde, C.J.H. van de; Nortier, J.W.R.; Guchelaar, H.J.
• Date: 2015-10-31
• Journal: Breast Cancer Research and Treatment
• Volume: 153
• Issue: 3
• Pages: 583 - 590
• DOI: doi:10.1007/s10549-015-3562-5